Merck KGaA is a global pharmaceutical, chemical and life science company with a history that began in and a future shaped by approximately , employees in countries. Merck KGaA s subsidiaries in North America operate using the umbrella brand EMD .
Quote | Merck Kgaa (OTCMKTS:MKGAF)
Last: | $165.33 |
---|---|
Change Percent: | 2.25% |
Open: | $154.8 |
Close: | $165.33 |
High: | $165.33 |
Low: | $154.8 |
Volume: | 1,092 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Merck Kgaa (OTCMKTS:MKGAF)
2024-04-10 12:49:59 ET Summary Thermo Fisher Scientific, Danaher Corporation, and Agilent Technologies are leading companies in the life science tools industry. Despite a long history of success with those firms, I believe long-term investors should diversify into growth opportuni...
2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...
Message Board Posts | Merck Kgaa (OTCMKTS:MKGAF)
Subject | By | Source | When |
---|---|---|---|
Emylers: MKGAF Financials 07/16/2014 02:53:05 Merck KGaA Period Ending Total Revenue Cost of Revenue | Emylers | investorshangout | 07/16/2014 7:53:02 AM |
Stock_Tracker: Latest Merck Kgaa Dm 5 (MKGAF) Headlines Merck KGaA Misses 2013 Earnings & Rev Ests - | Stock_Tracker | investorshangout | 03/10/2014 6:14:27 PM |
chartguy89: MKGAF 165.413 Stock Charts $MKGAF 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 7:58:23 PM |
chartguy89: MKGAF Stock Charts Last: +9.413 Thursday, February 27, 2014 at 11:59:25 PM $MKGAF | chartguy89 | investorshangout | 02/28/2014 4:59:36 AM |
News, Short Squeeze, Breakout and More Instantly...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...
Merck KGaA (OTC: MKGAF) (OTC: MKKGY) says its two Phase 3 EVOLUTION trials (evolutionRMS 1 and evolutionRMS 2) of evobruti...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...